Raymond James Financial »

Halozyme Therapeutics shares owned by Raymond James Financial

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by Raymond James Financial from 13F filings

Historical chart of Raymond James Financial investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Raymond James Financial consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Raymond James Financial

Quarter filed Position value Share count Share price at filing
2025-12-31 $37k 34k 1.08

More positions owned by Raymond James Financial

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Broadcom (AVGO)
Amazon (AMZN)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr Core Msci Eafe (IEFA)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Tr Core S&p500 Etf (IVV)
Wal-Mart Stores (WMT)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Meta Platforms Cl A (META)

View all positions for Raymond James Financial

Top funds holding Halozyme Therapeutics

Millennium Management
Tenor Capital Management
M&G
Jpmorgan Chase & Co
Nuveen
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
FMR
Point72 Asset Management
Calamos Advisors
MacKay Shields
Angelo, Gordon & Co
Advent Capital Management
Sonora Investment Management Group
Colony
Water Island Capital

View all funds holding Halozyme Therapeutics